Business Development

ProtAffin will partner is CellJammer^® discovery technology with Pharma and Biotech companies interested in optimally targeting proteins which interact with sugars such as glycosaminoglycans. Such protein-sugar interactions can make competing approaches difficult to optimally knock-down activity of such targets. ProtAffin is initially applying its technology to chemokines involved in inflammation, but will work with partners who have other proprietary targets under investigation. More details on potential structures of such Partnerships are available on request.

ProtAffin will also consider partnering its pipeline products such as PA401 with larger Pharma and Biotech companies when optimal risk-return points are reached.

ProtAffin is attending the upcoming conferences in 2010: 

1. BioBusiness, London: Jan 19-20
2. 8th Annual BioPartnering North America, Vancouver: Jan 24-26
3. 3rd Annual European Life Science CEO Forum, Zurich: Feb 11-12
4. 2010 BIO International Convention, Chicago: May 3-6
5. American Thoracic Society International Conference, New Orleans: May 14-19
6. BIOEquity Europe 2010, Zurich: May 19-20
7. Gordon Research Conference: Chemotactic Cytocines, Barga, Italy: May 30-June 4
8. European Respiratory Society Annual Congress, Barcelona: Sept 18-22

For more information please contact Dr. Jason Slingsby, CEO ()